Nhà máy Stada
Antihistamines & Antiallergics

Lorastad D


Pack size:

Box of 3 blisters x 10 film-coated tablets.



Each film-coated tablet contains desloratadine 5 mg.


24 months from the date of manufacturing.

Store in a well-closed container, in a dry place. Do not store above 30oC.

  • Indications and Dosage & Administration
  • Contraindications
  • Adverse reactions
  • Precautions

For the relief of symptoms associated with:

  • Allergic rhinitis.
  • Urticaria.

Administered orally. It can be taken with or without food.

  • Adults and adolescents (12 years of age and over):
    The recommended dose of Lorastad D is one tablet once a day.
  • Intermittent allergic rhinitis (presence symptoms for less than 4 days per week or for less than 4 weeks) should be managed in accordance with the evaluation of patient's disease history and the treatment could be discontinued after symptoms are resolved and reinitiated upon their reappearance.
  • In persistent allergic rhinitis (presence of symptoms for 4 days or more per week and for more than 4 weeks), continued treatment may be proposed to the patients during the allergen exposure period.

Or as advised by physicians.


  • Hypersensitivity to desloratadine, to loratadine or to any ingredient of the drug.


  • The most frequent adverse events reported were fatigue (1.2%), dry mouth (0.8%) and headache (0.6%).
  • In a clinical trial with 578 adolescent patients, 12 through 17 years of age, the most common adverse event was headache.
  • Other very rarely undesirable effects:
    Dizziness, somnolence, insomnia, psychomotor, hyperactivity, seizures.
    Tachycardia, palpitations.
    Abdominal pain, nausea, vomiting, dyspepsia, diarrhoea.
    Elevations of liver enzymes, increased bilirubin, hepatitis.
    Hypersensitivity reactions (such as anaphylaxis, angioedema, dyspnea, pruritus, rash, and urticaria).


  • The safety and efficacy of desloratadine in children below the age of 12 years have not been established.
  • In the case of severe renal insufficiency, desloratadine should be used with caution.
  • Pregnancy: Desloratadine was not teratogenic in animal studies. The safe use of the medicinal product during pregnancy has not been established. The use of desloratadine during pregnancy is therefore not recommended.
  • Lactation: Desloratadine is excreted into breast milk, therefore the use of desloratadine is not recommended in breastfeeding women.
  • In clinical trials that assessed the driving ability, no impairment occurred in patients receiving desloratadine. However, patients should be informed that very rarely some people experience drowsiness, which may affect their ability to drive or use machines.


Contact us

FACTORY 1: K63/1 Nguyen Thi Soc St., Xuan Thoi Dong, Hoc Mon, HCMC
Tel: +84 28 3718 2141 - Fax: +84 28 3718 2140

FACTORY 2: 40 Tu Do Avenue, VietNam-Singapore Industrial Park, Binh Duong
Tel: +84 274 376 7470 - Fax: +84 274 376 7469
Email : stada@stada.com.vn
Website: www.stada.com.vn

Visitors Counter